Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis

OBJECTIVE: Preclinical and clinical studies suggest that activation of the µ-opioid receptor may reduce overall survival and increase the risk for all-cause mortality in patients with cancer and noncancer pain. Methylnaltrexone, a selective, peripherally acting µ-opioid receptor antagonist, has demo...

Descripción completa

Detalles Bibliográficos
Autores principales: Webster, Lynn R, Brenner, Darren, Israel, Robert J, Stambler, Nancy, Slatkin, Neal E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
PRIMARY CARE & HEALTH SERVICES SECTION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977130/
https://www.ncbi.nlm.nih.gov/pubmed/36102822
http://dx.doi.org/10.1093/pm/pnac136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977130/
https://www.ncbi.nlm.nih.gov/pubmed/36102822
http://dx.doi.org/10.1093/pm/pnac136

Ejemplares similares